Gilead Sciences (GILD) 2025 10-K Earnings Analysis

Gross margin of 78.8% on a $29.4B revenue base is franchise-level pricing power. This reflects the HIV portfolio's dominance — Biktarvy as standard-of-care for treatment, Descovy for PrEP, and the emerging Lenacapavir franchise. When your drugs are the default regimen prescribed by HIV specialists worldwide, margin reflects clinical necessity rather than competitive negotiation. The 78.8% also reflects Gilead's efficient small-molecule manufacturing at scale.

OCF of $10.0B at 1.18x net income of $8.5B is excellent — meaning the business generates more cash than reported earnings, the hallmark of high-quality financials. The premium reflects favorable working capital dynamics (cash collected faster than expenses paid), depreciation/amortization exceeding capex, and the cash-efficient nature of pharmaceutical manufacturing at scale. Reported earnings understate true cash generation.

FCF of $9.5B represents a 32.3% FCF margin — among the highest in all of biopharma. The $500M gap between OCF and FCF reflects modest capex for manufacturing and R&D facilities. At $9.5B, Gilead generates enough free cash flow annually to fund substantial acquisitions, share buybacks, dividends, and pipeline R&D simultaneously. This level of FCF generation is the financial manifestation of franchise-level competitive advantage.

Revenue of $29.4B spans HIV (dominant), liver disease (Epclusa, Vemlidy), oncology (Trodelvy, Yescarta, Tecartus), and the emerging Lenacapavir franchise. While HIV remains the core (~60%+ of revenue), Gilead has meaningfully diversified into oncology through both internal development and acquisitions. The Livdelzi approval for PBC adds a new therapeutic area. Revenue concentration risk is lower than single-franchise biopharma companies.

Gilead's HIV franchise is the textbook example of pharmaceutical moat: Biktarvy is the standard-of-care single-tablet regimen for HIV treatment, prescribed by default by HIV specialists worldwide. The moat layers are deep — clinical data superiority, physician familiarity, resistance profile advantages, patient convenience (once-daily, single tablet), and the life-or-death nature of treatment adherence. Switching costs are not economic but clinical: changing a working HIV regimen risks treatment failure. This is as close to an unassailable pharmaceutical moat as exists.

Lenacapavir represents a genuine moat-widening innovation: the first capsid inhibitor for HIV, available as Sunlenca (twice-yearly treatment for resistant HIV) and Yeztugo (twice-yearly PrEP). Converting HIV from daily pills to biannual injections creates an entirely new category with no comparable competition. The PrEP indication (Yeztugo) is particularly transformative — replacing daily adherence with twice-yearly injections addresses the primary barrier to PrEP adoption. This is franchise extension through innovation, not mere lifecycle management.

78.8% gross margin on manufactured pharmaceuticals at $29.4B scale is exceptional — reflecting the pricing power of standard-of-care HIV medications, efficient manufacturing, and the life-necessity nature of the product portfolio. For context, this exceeds most biopharma companies and approaches software-like margins on physical products. The margin has been stable, confirming pricing power durability.

ROE at 37.5% is among the highest in large-cap biopharma, reflecting Gilead's ability to generate outsized returns on equity. With 14.1% goodwill/assets, the equity base is relatively clean — this ROE is not an artifact of depleted equity from write-downs but genuine capital efficiency. The HIV franchise generates returns far exceeding the cost of capital, confirming economic moat.

FCF margin of 32.3% ($9.5B/$29.4B) is exceptional — generating nearly one-third of revenue as free cash flow. This provides enormous capital allocation flexibility: Gilead can simultaneously fund R&D pipeline investment, acquire complementary assets, pay dividends, and repurchase shares. The high FCF margin reflects both pricing power (78.8% GM) and capital-light manufacturing (modest capex relative to revenue).

FCF at 1.12x net income confirms earnings quality and capital efficiency — the business converts more than 100% of accounting profit into distributable cash. This strong conversion reflects the capital-light nature of pharmaceutical manufacturing once facilities are established, favorable working capital dynamics, and disciplined capital expenditure management.

Goodwill at 14.1% of assets is moderate for a company that has made significant acquisitions (Kite Pharma for CAR-T, Immunomedics for Trodelvy). The acquisitions have expanded Gilead's oncology franchise and appear to be generating returns. The goodwill level does not suggest excessive acquisition premiums or empire-building — it reflects strategic portfolio expansion.

Capital allocation extends the HIV cash flow engine into oncology (Trodelvy for breast/bladder cancer, Yescarta/Tecartus CAR-T therapies), liver disease (Livdelzi for PBC, Vemlidy for HBV), and emerging therapeutic areas. The 25+ product commercial portfolio demonstrates successful diversification beyond the original HIV and HCV franchises. Management is deploying franchise cash flows into areas with genuine unmet need and competitive defensibility.